BeiGene, Ltd. Files 8-K with Financial Statements
Ticker: BEIGF · Form: 8-K · Filed: Apr 23, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: BGNE
TL;DR
BeiGene filed an 8-K with financial docs, check it for latest numbers.
AI Summary
On April 23, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating it's an update or disclosure related to the company's financial reporting. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides updated financial information for BeiGene, Ltd., which is crucial for investors to assess the company's financial health and performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Mourant Governance Services (Cayman) Limited (company) — Agent for service of process
- April 23, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by BeiGene, Ltd.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on April 23, 2024.
What is BeiGene, Ltd.'s principal executive office address?
BeiGene, Ltd.'s principal executive offices are located at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands.
What is BeiGene, Ltd.'s IRS Employer Identification Number?
BeiGene, Ltd.'s IRS Employer Identification Number is 98-1209416.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-23 16:13:55
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
Filing Documents
- bgne-20240423.htm (8-K) — 36KB
- a8-kxtislex23apr2024xex991.htm (EX-99.1) — 23KB
- 0001651308-24-000039.txt ( ) — 186KB
- bgne-20240423.xsd (EX-101.SCH) — 2KB
- bgne-20240423_lab.xml (EX-101.LAB) — 21KB
- bgne-20240423_pre.xml (EX-101.PRE) — 12KB
- bgne-20240423_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 23, 2024, BeiGene, Ltd. announced that the European Commission approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release titled "BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer" issued by BeiGene, Ltd. on April 23, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 99.1 Press release titled "BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer" issued by BeiGene, Ltd. on April 23, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: April 23, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel